Ajay Aggarwal
Guy's and St Thomas' NHS Foundation Trust
CancerInternal medicineSurgeryOncologyHealth careIntensive care medicineProstateProstatectomyMEDLINEProstate cancerPopulationPalliative careCoronavirus disease 2019 (COVID-19)Confidence intervalHealth policyRadiation therapyFamily medicineColorectal cancerBreast cancerGeneral surgeryMedicinePandemic
98Publications
18H-index
1,770Citations
Publications 101
Newest
#1Jemma Boyle (Lond: University of London)H-Index: 1
#2Angela Kuryba (RCS: Royal College of Surgeons of England)H-Index: 8
Last. Ajay Aggarwal (Guy's and St Thomas' NHS Foundation Trust)H-Index: 18
view all 8 authors...
The impact of cycle completion rates of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer in real-world practice is unknown. We assessed its impact, and that of treatment modification, on 3-year cancer-specific mortality. Four thousand one hundred and forty-seven patients with pathological stage III colon cancer undergoing major resection from 2014 to 2017 in the English National Health Service were included. Chemotherapy data came from linked national administrative datasets. C...
Source
#1Julie Nossiter (Lond: University of London)H-Index: 8
#2Melanie Morris (Lond: University of London)H-Index: 9
Last. Paul Cathcart (Guy's and St Thomas' NHS Foundation Trust)H-Index: 17
view all 10 authors...
Improvements in short-term outcomes have been reported for hospitals with higher radical prostatectomy (RP) volumes. However, the association with longer-term functional outcomes is unknown. All patients diagnosed with non-metastatic prostate cancer in the English NHS between 2014 and 2016 who underwent RP (N = 10,089) were mailed a survey ≥18 months after diagnosis. Differences in patient-reported urinary continence and sexual function (EPIC-26 on scale from 0 to 100) by hospital volume group (...
Source
#1Matthew G. Parry (Lond: University of London)H-Index: 8
#2Jemma Boyle (Lond: University of London)H-Index: 1
Last. Heather Payne (UCL: University College London)H-Index: 11
view all 11 authors...
Many factors are implicated in the potential ‘under-treatment’ of prostate cancer but little is known about the between-hospital variation. The National Prostate Cancer Audit (NPCA) database was used to identify high-risk localised or locally advanced prostate cancer patients in England, between January 2014 and December 2017, and the treatments received. Hospital-level variation in radical local treatment was explored visually using funnel plots. The intra-class correlation coefficient (ICC) qu...
Source
#1Susannah StanwayH-Index: 8
#2Mark LodgeH-Index: 1
Last. Amanda NadinH-Index: 1
view all 14 authors...
Summary null null Cancer mortality rates in low-income and middle-income countries (LMICs) are unacceptably high, requiring both collaborative global effort and in-country solutions. Experience has shown that working together in policy, clinical practice, education, training, and research leads to bidirectional benefit for LMICs and high-income countries. For over 60 years, the UK National Health Service has benefited from recruitment from LMICs, providing the UK with a rich diaspora of trained ...
2 CitationsSource
#1Adam Fundytus (Queen's University)H-Index: 4
#2J.C. Wells (Queen's University)
Last. Ajay Aggarwal (Lond: University of London)H-Index: 18
view all 12 authors...
Abstract null null Aims null Most randomised controlled trials (RCTs) in oncology are now funded by the pharmaceutical industry. We explore the extent to which RCT design, results and interpretation differ between industry-funded and non-industry-funded RCTs. null null null Materials and methods null In this cross-sectional analysis, a structured literature search was used to identify all oncology RCTs published globally during 2014–2017. Industry funding was identified based on explicit stateme...
Source
#1Jemma Boyle (Lond: University of London)H-Index: 1
#2Gemma Hegarty (The Royal Marsden NHS Foundation Trust)
Last. Ajay Aggarwal (Guy's and St Thomas' NHS Foundation Trust)H-Index: 18
view all 10 authors...
Abstract null null Purpose null Real-World Data (RWD) studies are increasingly used to support regulatory approvals, reimbursement decisions, and changes in clinical practice for novel cancer drugs. However, few studies have systematically appraised their quality or compared outcomes to pivotal trials. null null null Methods null All RWD studies (2010–2019) for drugs approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) from 2010 to 2015 for solid organ tumours i...
Source
#1Jemma Boyle (Lond: University of London)H-Index: 1
#2Angela Kuryba (RCS: Royal College of Surgeons of England)H-Index: 8
Last. Kate Walker (Lond: University of London)H-Index: 18
view all 7 authors...
Abstract null null Background null We used a structured approach to validate chemotherapy information derived from a national routinely collected chemotherapy dataset and from national administrative hospital data. null null null Methods null 10,280 patients who had surgical resection with stage III colon cancer were included. First, we compared information derived from the national chemotherapy dataset (SACT) and from the administrative hospital dataset (HES) in the English NHS with respect to ...
1 CitationsSource
#1Louis Fox ('KCL': King's College London)H-Index: 3
#2Ajay Aggarwal ('KCL': King's College London)H-Index: 18
Last. Mieke Van Hemelrijck ('KCL': King's College London)H-Index: 36
view all 10 authors...
Introduction: The COVID-19 pandemic has had substantial impacts on cancer services. National Cancer Waiting Times (CWT) targets in England stipulate that individuals referred from primary care for suspected cancer must receive treatment for any confirmed cancer within 62 days of referral. This analysis aimed to broadly quantify the association between COVID-19 hospitalizations by England region, and the proportion of confirmed cancer patients breaching the 62-day target in that region a month la...
Source
Source
#2Jemma M. Boyle (RCS: Royal College of Surgeons of England)H-Index: 2
#3Helen A Blake (RCS: Royal College of Surgeons of England)
Last. Ajay Aggarwal (Lond: University of London)H-Index: 18
view all 8 authors...
OBJECTIVE: To compare the management and outcomes of colorectal cancer (CRC) patients during the first two months of the COVID-19 pandemic with the preceding six months. BACKGROUND: The pandemic has affected the diagnosis and treatment of CRC patients worldwide. Little is known about the safety of major resection and whether creating ‘cold’ sites (COVID-free hospitals) is effective. METHODS: A national study in England used administrative hospital data for 14,930 CRC patients undergoing surgery ...
Source